Actelion Ltd (ATLN.VX)

ATLN.VX on Virt-X Level 1

27 Mar 2015
Change (% chg)

CHF0.80 (+0.71%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ATLN.VX


Actelion Ltd is a Swiss biopharmaceutical holding company that focuses on the discovery, development and commercialization of small molecule drugs. The Company has four approved drugs on the market: Tracleer, an oral dual endothelin receptor antagonist; Veletri, a prostanoid vasodilator; Ventavis, an inhaled formulation of... (more)


Beta: 1.03
Market Cap(Mil.): CHF12,942.16
Shares Outstanding(Mil.): 114.13
Dividend: 1.30
Yield (%): 1.06


  ATLN.VX Industry Sector
P/E (TTM): 22.18 137.41 40.78
EPS (TTM): 5.11 -- --
ROI: 28.68 -0.59 16.19
ROE: 32.72 -2.32 17.04
Search Stocks

BRIEF-Actelion announces commencement of share repurchase programme

* Has received approval from relevant authorities to launch repurchase of up to 10 million shares (8.76 percent of currently issued capital), over three years Source text - Further company coverage: (Gdynia Newsroom)

23 Mar 2015

BRIEF-Actelion says NDA for selexipag accepted by the US FDA

* Actelion says new drug application for selexipag, or uptravi, is accepted by the U.S. Food and Drug Administration with a standard review time Further company coverage: (Reporting By Zurich Slot)

03 Mar 2015

UPDATE 2-Actelion shares fall after it lowers 2015 forecasts

* Tracleer sales of 328 mln francs miss 356 mln forecast (Adds analyst comment, detail)

16 Feb 2015

European shares mark time ahead of euro zone meeting

* FTSEurofirst 300 down 0.1 pct, hovers just below 7-year high

16 Feb 2015

European shares steady ahead of euro zone meeting

PARIS, Feb 16 - European stocks were steady in early trading on Monday, taking a breather following last week's sharp gains, as investors awaited a euro zone finance ministers' meeting in Brussels to see if common ground will be found with Greece's new government.

16 Feb 2015

Actelion hikes dividend, plans share buyback as profit meet views

ZURICH, Feb 16 - Switzerland's Actelion on Monday said it will hike its dividend by 8 percent and buy back as many as 10 million of its own shares in the next three years, following full-year results that met analyst expectations.

16 Feb 2015

BRIEF-Actelion submits selexipag for EMA marketing authorisation in patients with pulmonary arterial hypertension

* Announced on Monday the submission of centralized Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for selexipag (Uptravi(R)) in treatment of pulmonary arterial hypertension (PAH)

02 Dec 2014

Actelion lifts 2014 profit view on strong Opsumit launch

ZURICH - Actelion raised its 2014 earnings guidance on Tuesday for the third time this year, buoyed by a strong start to its new heart and lung drug and better-than-expected profit in the third quarter.

21 Oct 2014

UPDATE 2-Actelion lifts 2014 profit view on strong Opsumit launch

* Shares up 6.8 pct (Adds details on rival products, analyst, shares)

21 Oct 2014

BRIEF-Actelion shares open up 4 pct

* Actelion shares open up 4 percent after raising its full-year guidance. Further company coverage: (Reporting by Joshua Franklin)

21 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
Provider: ValuEngine, Inc.
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks